Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

Clinical trial registration, sponsored by Joshua Woolley, MD, PhD, registered 21 Jun 2021.

Phase 2 · completed · n = 12

Tags: Registry, Psilocybin, Depression, Anxiety, Neurological.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 11: 20 new trials registered

New registrations include psilocybin for methamphetamine use disorder, borderline personality disorder, nicotine craving and premenstrual dysphoric disorder, and a National Institute on Aging trial pairing psilocybin with cognitive training. Results were posted for psilocybin in depression and anxiety in Parkinson's disease.

How much weight it carries: Registrations show what is being attempted, not what was found. (Registry, Plans, not results)

Weekly Science Digest, 29 Aug 2026 to 4 Sep 2026, finding 6: In the clinic

results posted for psilocybin therapy in depression and anxiety in Parkinson's disease, run by Joshua Woolley

How much weight it carries: Trial registry movements: what is being attempted, not what was found. (Registry, Plans, not results)

Read the original

—
Node—
Statuslive
Throughput—